Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

PURPOSE: To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 43 patients with BRAF V600–mutant mCRC were treated with dabrafenib (150 mg twice...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P., Kopetz, Scott
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2015
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669588/
https://ncbi.nlm.nih.gov/pubmed/26392102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2471
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak